Research Highlights:
- A new analysis found SGLT-2 inhibitors, a diabetes medication, decreased the risk of cardiovascular death and hospitalization for heart failure, in high-risk patients regardless of whether they have Type 2 diabetes.
- Pooled results from 13 major trials of empagliflozin and similar medicines showed that study participants who received the SGLT-2 inhibitor were 14% less likely to die from cardiovascular disease. Participants treated with these medicines were also 23% less likely to die from cardiovascular disease or be hospitalized for heart failure compared to participants who took a placebo.
This data is scheduled to be simultaneously published in The Lancet.
CHICAGO, Nov. 6, 2022 — SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"Many studies of empagliflozin and other similar medicines called SGLT-2 inhibitors (sodium-glucose co-transporter-2 inhibitors) have demonstrated that these medicines are safe for people with Type 2 diabetes," said co-principal investigator David Preiss, Ph.D., associate professor in the Medical Research Council Population Health Research Unit at the University of Oxford, Oxford Population Health in the U.K. "And we now have very good evidence that they lower the chance of dying from vascular disease or being hospitalized for heart failure among people with chronic kidney disease, heart failure, or Type 2 diabetes and cardiovascular disease. We therefore hope that SGLT-2 inhibitors may be used widely to treat people with these conditions in many countries."
The researchers combined the results from 13 major clinical trials of SGLT-2 inhibitors to consider the effects on kidney disease progression, acute kidney injury and cardiovascular death or hospitalization for heart failure, in participants with or without Type 2 diabetes. According to Preiss, the analysis confirmed important benefits of SGLT-2 inhibitors on both major cardiovascular and kidney disease outcomes:
- SGLT-2 inhibitors reduced the risk of cardiovascular death by 14%, with similar results among participants with or without Type 2 diabetes.
- SGLT-2 inhibitors also reduced the risk of cardiovascular death or hospitalization for heart failure by 23%, with similar results among the participants with or without Type 2 diabetes.
- The risk of kidney disease progression was reduced by 37% overall, again with similar effects among participants regardless of Type 2 diabetes status.
- Based on the trial data, for every 1,000 participants with heart failure treated for a year, 34 with diabetes and 22 without diabetes avoided cardiovascular death or hospitalization for heart failure.
- For every 1,000 participants with chronic kidney disease treated for a year, 11 with diabetes and 15 without diabetes avoided worsening kidney disease.
The meta-analysis included results from the EMPA-KIDNEY Trial, the largest study to assess the use of SGLT-2 inhibitors in participants with chronic kidney disease. Previous research linked the medicine with a decreased risk of hospitalization for heart failure and a decreased risk of worsening kidney disease among people with Type 2 diabetes. "What remained unclear is whether this medicine may have the same protective effect among people not diagnosed with Type 2 diabetes," Preiss said.
EMPA-KIDNEY researchers enrolled 6,609 study participants in eight countries: Germany, the United States, the United Kingdom, China, Malaysia, Japan, Canada and Italy. Participants' average age was 64 years, and more than half were white adults, 36% were Asian adults and 4% were Black adults. All participants had evidence of kidney disease for at least 3 months; more than 25% had cardiovascular disease; and slightly less than half had Type 2 diabetes. Between May 2019 and April 2021, participants were randomly assigned to empagliflozin or a placebo. Follow-up was for an average of two years.
Results of the EMPA-KIDNEY trial, published two days ago on November 4, 2022, showed that among the participants in the empagliflozin group, the risk of worsening kidney disease and death from cardiovascular disease decreased by 28%, with similar benefits for participants with or without Type 2 diabetes. The rate of cardiovascular events was lower than anticipated. Though the reduction in major cardiovascular events with empagliflozin treatment was not statistically significant in the trial, the results for these outcomes were entirely consistent with results from other trials.
"Our results suggest that SGLT-2 inhibitors such as empagliflozin should be offered to all adults who may benefit from the treatment, to reduce the risk of kidney disease progression and cardiovascular complications in people with chronic kidney disease, regardless of whether they have Type 2 diabetes or not," Preiss said.
Co-authors are William Herrington, M.D., and Richard Haynes, D.M., on behalf of the Oxford Population Health Renal Studies Group and the SGLT2 Meta-analysis Cardio-renal Trialists' Consortium (SMART-C). Authors' disclosures are listed in the abstract.
The study was funded by core funding to the Medical Research Council Population Health Research Unit at the University of Oxford from the UK Medical Research Council. EMPA-KIDNEY was funded by Boehringer Ingelheim and Eli Lilly and Company.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
